Ключевые слова:
pregnancy termination, medical abortion, vacuum aspiration, curettage, mifepristone, complications, reproductive health.Библиографические ссылки
1. Baulieu E.E. RU 486: an antiprogestin steroid with contraceptive activity in women // Contraception, Fertilité, Sexualité. 1987. Vol. 15. No. 6. P. 1045–1047.
2. Coulier R., Kapp N., Gulmezoglu A.M. et al. Medical methods for first trimester abortion // Cochrane Database of Systematic Reviews. 2011. Issue 11. Art. No.: CD002855.
3. Grimes D.A., Benson J., Singh S. et al. Unsafe abortion: the preventable pandemic // The Lancet. 2006. Vol. 368. No. 9550. P. 1908–1919.
4. Gurtovoy B.L., Serov V.N., Makatsaria A.D. Medicamentous pregnancy prevention: guidance for doctors. Moscow: GEOTAR-Media, 2010. 224 p.
5. Raymond E.G., Grimes D.A. The comparative safety of legally induced abortion and childbirth in the United States // Obstetrics & Gynecology. 2012. Vol. 119. No. 2. P. 215–219.
6. Saveleva G.M., Sukhikh G.T., Serov V.N. Obstetrics: national leadership. Moscow: GEOTAR-Media, 2015. 1088 p.
7. Uzbekistan Republic Health storage Ministry of Reproductive Health Program 2021–2025. Tashkent, 2021. 68 p.
8. Winikoff B., Dzuba I.G., Creinin M.D. et al. Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial // Obstetrics & Gynecology. 2008. Vol. 112. No. 6. P. 1303–1310.
9. World Health Organization. Abortion care guidelines. Geneva: WHO, 2022. 184 p.
10. Yuldosheva S.N., Karimova M.Kh. Modern reproductive health issues // Uzbekistan Medicine Journal. 2020. No. 3. P. 45–49.
